Immutep Limited

Equities

IMM

AU000000IMM6

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:53 2024-05-16 am EDT			5-day change	1st Jan Change
0.435 ^AUD	-2.25%		-6.45%	+26.09%

May. 15	Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	MT
May. 15	Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	CI

Prima Biomed Ltd. Announces Executive Changes

March 08, 2016 at 01:13 am EST

Prima BioMed Ltd. announced that General Counsel and Company Secretary, Deanne Miller, will be on maternity leave with effect from March 16, 2016. Mr. Tom Bloomfield has been appointed as Joint Company Secretary effective immediately for the period of Ms. Miller's maternity leave. Mr. Bloomfield is General Manager of Corporate Secretarial Services at Boardroom Pty Limited.

He acts as Company Secretary to a small number of ASX listed, unlisted and private companies in Australia in numerous industry sectors. Mr. Bloomfield is a Chartered Company Secretary, Fellow of ICSA (Institute of Chartered Secretaries and Administrators) and Member of the Australian Institute of Company Directors.

Latest news about Immutep Limited

Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	May. 15	MT
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	May. 15	CI
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	May. 02	CI
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	May. 01	MT
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024	Apr. 30	CI
Canaccord Starts Immutep at Buy, Price Target is AU$1.00	Apr. 29	MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	Apr. 25	CI
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	Apr. 24	MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	Apr. 24	CI
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	Apr. 18	CI
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	Apr. 18	MT
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Apr. 17	CI
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	Apr. 17	MT
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial	Apr. 16	MT
Encouraging results for Immutep's cancer therapies	Mar. 25	FI
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti	Mar. 05	CI
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss	Feb. 27	MT
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer	Jan. 04	CI
Immutep Doses First Patient in Cancer Trial	Jan. 03	MT
Immutep Limited Announces Change of Registered Office Address	Dec. 21	CI
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Dec. 21	CI
Immutep Receives $1.7 Million Research, Development Tax Incentive From French Government	Dec. 07	MT
Immutep Secures 1.6 Million Euro French R&D Tax Rebate for 2022	Dec. 06	MT
Immutep Says More Sites Added to Insight-003 Phase 1 Trial for Lung Cancer Treatment	Nov. 22	MT

Chart Immutep Limited

Duration

Period

More charts

Company Profile

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Sector

Biotechnology & Medical Research

Calendar

2024-05-30 - American Society of Clinical Oncology Annual Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Immutep Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.445 AUD

Average target price

0.978 AUD

Spread / Average Target

+119.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUTEP LIMITED	+26.09%	354M
MODERNA, INC.	+29.77%	49.46B
IQVIA HOLDINGS INC.	+1.00%	42.58B
LONZA GROUP AG	+49.96%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.64B
BIO-TECHNE CORPORATION	+8.22%	13.16B
MEDPACE HOLDINGS, INC.	+32.41%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.01%	12.1B

Other Biotechnology & Medical Research